This Government Contract opportunity from Department Of Veterans Affairs was posted on June 5, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
Q301--New - Referral Lab Testing NTX
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The Department of Veterans Affairs intends to negotiate and award a sole-source, out-of-scope modification to an existing IDIQ Firm-Fixed-Price contract currently held by Mayo Collaborative Services, LLC. This modification will expand the scope by adding specific referral laboratory testing services to the Pathology and Laboratory Department at the North Texas Veterans Health Care facility in Dallas, TX. The additional tests include a variety of genetic mutation analyses, lymphocytic leukemia diagnostics, full gene analyses, and evaluations pertinent to liver and CNS conditions, with estimated annual volumes ranging from three to five tests per item. This acquisition is being conducted under the statutory authority provided by 41 U.S.C. 1901 and FAR guidelines allowing for simplified acquisition procedures exempt from certain competitive requirements. Although this notice is not a solicitation for competitive proposals, the agency will consider capability statements submitted by interested parties to help determine if future procurements should be competitive. The final decision to award without competition remains at the government's discretion. The contract is managed by the Network Contract Office 17 with contact information provided for the contracting specialist managing the process.
General Info
Agency
NAICS
Place of Performance
TXSet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
Item Number Test Name CPT Codes Estimated Annual Test Volume 3032 4032 UBA1Mutation Quant 81403 4 3033 4033 Prothrobmin G20210A Mutation, Blood 81240-F2 4 3034 4034 TP53 Mutation, NGS 88381, 81351 5 3035 4035 Chronic Lymphocytic Leukemia FISH Diagnostics 88271x12, 88275x6, 88291 4 3036 4036 PKLR Full gene analysis 81405 4 3037 4037 B-cell lymphoma NGS 81450 4 3038 4038 UDP-Glucuronosyltransferase 1A1 (UGT1A1) 81404 4 3039 4039 Copper, Liver Tissue 82525 5 3040 4040 CNS Demyelinating Disease Evaluation, Serum 86053,86363 3
The statutory authority permitting this sole source acquisition is 41 U.S.C. 1901 as implemented by RFO FAR 6.103-1 (c ). Acquisitions conducted under simplified acquisition procedures are exempt from the requirements in FAR Part 6. A copy of the justification will made publicly available within 14 days of modification execution in accordance with RFO FAR 6.301. This notice of intent is NOT a request for competitive proposals. However, all responsible sources may submit a capability statement which shall be considered by the agency. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement in the future. A determination by the Government not to compete this proposed action based upon responses to this notice is solely within the discretion of the Government
